Innovation Pathways in the NHS: An Introductory Review (Englisch)
Freier Zugriff
- Neue Suche nach: Arora, Anmol
- Weitere Informationen zu Arora, Anmol:
- https://orcid.org/0000-0003-4881-8293
- Neue Suche nach: Wright, Andrew
- Neue Suche nach: Cheng, Mark
- Neue Suche nach: Khwaja, Zahra
- Neue Suche nach: Seah, Matthew
- Weitere Informationen zu Seah, Matthew:
- https://orcid.org/0000-0002-5850-125X
- Neue Suche nach: Arora, Anmol
- Weitere Informationen zu Arora, Anmol:
- https://orcid.org/0000-0003-4881-8293
- Neue Suche nach: Wright, Andrew
- Neue Suche nach: Cheng, Mark
- Neue Suche nach: Khwaja, Zahra
- Neue Suche nach: Seah, Matthew
- Weitere Informationen zu Seah, Matthew:
- https://orcid.org/0000-0002-5850-125X
In:
Therapeutic Innovation & Regulatory Science
;
55
, 5
; 1045-1058
;
2021
-
ISSN:
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Innovation Pathways in the NHS: An Introductory Review
-
Beteiligte:Arora, Anmol ( Autor:in ) / Wright, Andrew ( Autor:in ) / Cheng, Mark ( Autor:in ) / Khwaja, Zahra ( Autor:in ) / Seah, Matthew ( Autor:in )
-
Erschienen in:Therapeutic Innovation & Regulatory Science ; 55, 5 ; 1045-1058
-
Verlag:
- Neue Suche nach: Springer International Publishing
- Neue Suche nach: Springer Nature
-
Erscheinungsort:[New York]
-
Erscheinungsdatum:2021
-
ISSN:
-
ZDBID:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
- Neue Suche nach: 44.38
- Weitere Informationen zu Basisklassifikation
-
Schlagwörter:
-
Klassifikation:
BKL: 44.38 Pharmakologie -
Datenquelle:
Inhaltsverzeichnis – Band 55, Ausgabe 5
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 907
-
An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice ViolationsJung, Miah / Swann, Rachelle M. / Anantha, Michelle S. / Jamali, Faranak et al. | 2021
- 918
-
Biennial Analysis of Medication Guide Length and Estimated Readability for New Molecular Entity Drugs, 2011–2017Jones, Paul R. / Walther, Elisabeth J. / Nguyen, Andrew / Santiago, Jonas / Pearsall, Bryon M. et al. | 2021
- 926
-
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master TrialRosenberg, Len / Levaux, Hugh / Levine, Ross L. / Shah, Amit / Denmark, James / Hereema, Nyla / Owen, Melanie / Kalk, Spencer / Kenny, Nicholas / Vinson, Gene et al. | 2021
- 936
-
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for ActionCavaller-Bellaubi, Maria / Faulkner, Stuart D. / Teixeira, Bryan / Boudes, Mathieu / Molero, Eva / Brooke, Nicholas / McKeaveney, Laura / Southerton, Jeffrey / Vicente, Maria José / Bertelsen, Neil et al. | 2021
- 954
-
Evaluating Metrics Applied to the Medical Science Liaison (MSL) Role: A Survey-Based Study of Canadian MSL LeadersSaleem, Munaza / Cesario, Lisa / Wilcox, Lisa / Haynes, Marsha / Collin, Simon / Langlois, Peter / Kenyon, Stevie / Chilelli, Andrew et al. | 2021
- 966
-
Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific OutcomesMadeira, C. / Hořavová, L. / dos Santos, F. / Batuca, J. R. / Nebeska, K. / Součková, L. / Kubiak, C. / Demotes, J. / Demlová, R. / Monteiro, E. C. et al. | 2021
- 979
-
Cutting Through the “Gray Area”: An Analysis of the IBC Regulatory Oversight of Applications of CRISPR Technology in Clinical ResearchWeiss, Westley F. et al. | 2021
- 984
-
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 PandemicQu, Yongming / Lipkovich, Ilya et al. | 2021
- 989
-
Addressing Bias in Responder Analysis of Patient-Reported OutcomesCappelleri, Joseph C. / Chambers, Richard et al. | 2021
- 1001
-
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity IssuesLi, Qian H. / Deng, Qiqi / Ting, Naitee et al. | 2021
- 1006
-
Characterizing Pain Points in Clinical Data Management and Assessing the Impact of Mid-Study UpdatesHarper, Beth / Smith, Zachary / Snowdon, Jane / DiCicco, Robert / Hekmat, Rezzan / Weeraratne, Dilhan / Getz, Ken et al. | 2021
- 1013
-
Correction to: Characterizing Pain Points in Clinical Data Management and Assessing the Impact of Mid-Study UpdatesHarper, Beth / Smith, Zachary / Snowdon, Jane / DiCicco, Robert / Hekmat, Rezzan / Weeraratne, Dilhan / Getz, Ken et al. | 2021
- 1014
-
The Role of Regulatory Sciences from the Perspective of the Cuban Medicines Regulatory Agency: The Impact of COVID-19 in Promoting Innovation, Cooperation and Scientific ThinkingRomeu, Belkis / Rodríguez, Yaquelín / Bendiner, Silvia et al. | 2021
- 1019
-
The Use of External Controls in FDA Regulatory Decision MakingJahanshahi, Mahta / Gregg, Keith / Davis, Gillian / Ndu, Adora / Miller, Veronica / Vockley, Jerry / Ollivier, Cecile / Franolic, Tanja / Sakai, Sharon et al. | 2021
- 1036
-
Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral ExplanationOger, Alexandra / Torqui, Aimad / Kester, Robert / Wissink, Sacha et al. | 2021
- 1045
-
Innovation Pathways in the NHS: An Introductory ReviewArora, Anmol / Wright, Andrew / Cheng, Mark / Khwaja, Zahra / Seah, Matthew et al. | 2021
- 1059
-
Patient Engagement Initiatives in Clinical Trials: Recent Trends and ImplicationsSine, Shalome / de Bruin, Annick / Getz, Kenneth et al. | 2021
- 1066
-
Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug DevelopmentMénard, Timothé / Barros, Alaina / Ganter, Christopher et al. | 2021
- 1075
-
Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive AnalysisEzaki, Asami / Hirakawa, Akihiro / Hanaoka, Hideki / Uyama, Yoshiaki et al. | 2021
- 1082
-
Measuring What Matters for Children: A Systematic Review of Frequently Used Pediatric Generic PRO InstrumentsArsiwala, Tasneem / Afroz, Nuzhat / Kordy, Kattayoun / Naujoks, Christel / Patalano, Francesco et al. | 2021
- 1096
-
Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence StudiesKajiwara, Eiji / Kamizato, Haruki / Shikano, Mayumi et al. | 2021
- 1101
-
Prescribing Information for Antihypertensive Medications Lacks Dose-Specific Blood Pressure ResponseVyas, Ruchi / Cooke, Catherine E. et al. | 2021
- 1103
-
Government Pharmaceutical Development to Address High Prices: Challenges AheadDarrow, Jonathan J. et al. | 2021